Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E32.81 EPS (ttm)2.33 Insider Own0.10% Shs Outstand2.61B Perf Week3.27%
Market Cap199.16B Forward P/E14.56 EPS next Y5.24 Insider Trans-38.68% Shs Float2.58B Perf Month-7.94%
Income6.22B PEG3.30 EPS next Q1.05 Inst Own78.30% Short Float1.26% Perf Quarter4.33%
Sales42.29B P/S4.71 EPS this Y27.80% Inst Trans0.15% Short Ratio2.98 Perf Half Y5.19%
Book/sh10.21 P/B7.48 EPS next Y12.17% ROA7.30% Target Price87.36 Perf Year27.04%
Cash/sh3.40 P/C22.47 EPS next 5Y9.94% ROE19.90% 52W Range56.26 - 83.85 Perf YTD-0.09%
Dividend2.20 P/FCF63.53 EPS past 5Y9.60% ROI11.20% 52W High-8.96% Beta0.62
Dividend %2.88% Quick Ratio0.90 Sales past 5Y-0.80% Gross Margin68.10% 52W Low35.70% ATR1.42
Employees69000 Current Ratio1.20 Sales Q/Q5.40% Oper. Margin19.60% RSI (14)38.30 Volatility2.24% 1.74%
OptionableYes Debt/Eq0.94 EPS Q/Q21.20% Profit Margin14.70% Rel Volume1.21 Prev Close74.73
ShortableYes LT Debt/Eq0.74 EarningsApr 30 BMO Payout82.00% Avg Volume10.95M Price76.34
Recom1.80 SMA20-3.89% SMA50-4.94% SMA2003.55% Volume13,245,565 Change2.15%
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Apr-25-19 05:19PM  Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Business Wire
02:55PM  The Top 10 Biotechnology Companies (JNJ, ROG.VX) Investopedia
02:52PM  Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis Zacks
11:50AM  Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales? Zacks
10:08AM  Pfizer Stock Has Positive and Negative Catalysts Going Into Results InvestorPlace
08:00AM  Merck and Viola Davis to Debut A Touch of Sugar During Tribeca Film Festival® PR Newswire
Apr-24-19 05:45PM  Merck (MRK) Gains As Market Dips: What You Should Know Zacks
03:42PM  Why Investors Should Buy the Dip in MRK Stock InvestorPlace
01:50PM  AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Heres what to expect MarketWatch
Apr-23-19 03:54PM  Kidney-Cancer Market: Good for Patients, Hard for Investors Motley Fool
11:09AM  Why Is Bristol-Myers Near 52-Week Lows? InvestorPlace
10:44AM  What's in the Cards for AstraZeneca (AZN) in Q1 Earnings? Zacks
10:35AM  The Zacks Analyst Blog Highlights: Wells Fargo, UnitedHealth, Merck, Schwab and Raytheon Zacks
10:32AM  Earnings Preview: Merck (MRK) Q1 Earnings Expected to Decline Zacks
06:30AM  BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston GlobeNewswire
Apr-22-19 07:37AM  Merck's Keytruda wins FDA approval as combination therapy for kidney cancer Reuters
06:59AM  Merck's Keytruda wins FDA approval as combination therapy for kidney cancer Reuters
06:45AM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) Business Wire
Apr-20-19 07:45AM  You can capture a dividend above 5% and still enjoy stock-market growth MarketWatch
Apr-18-19 05:00PM  Pharmaceutical ETFs Catch Healthcare Contagion ETF Trends
04:13PM  Keeley Funds Comments on Versum Materials GuruFocus.com
03:17PM  Health-care drama has now spread to biopharma stocks MarketWatch
11:29AM  Clovis Focuses on Rubraca Label Expansion, Competition Stiff Zacks
10:59AM  Can Q1 Earnings Lift Healthcare ETFs Higher? Zacks
10:22AM  Here Are the Key Takeaways From J&J's Q1 Earnings Report Zacks
09:17AM  Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline Zacks
Apr-17-19 01:21PM  Health-care stocks keep getting hammered Wall Street says this is why MarketWatch
12:44PM  EMD FINANCE LLC -- Moody's affirms Merck KGaA's ratings; stable outlook Moody's
12:11PM  Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's exchange notes; under review for downgrade Moody's
11:19AM  Top Analyst Reports for Wells Fargo, UnitedHealth & Merck Zacks
11:03AM  Gilead Collaborates With Insitro to Develop NASH Therapies Zacks
10:52AM  3 Charts That Suggest Health Care Stocks Are Headed Lower Investopedia
10:13AM  3 Charts That Suggest Healthcare Stocks Are Headed Lower Investopedia
Apr-16-19 10:58AM  J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View Zacks
09:15AM  Why Merck (MRK) is a Top Dividend Stock for Your Portfolio Zacks
08:10AM  The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives Benzinga
06:27AM  Merck Financial Services GmbH -- Moody's affirms Merck KGaA's ratings; stable outlook Moody's
Apr-15-19 05:50PM  Merck (MRK) Dips More Than Broader Markets: What You Should Know Zacks
01:53PM  Bristol-Myers' Shareholders Vote for Celgene Acquisition Zacks
10:07AM  J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer Zacks
Apr-13-19 07:00AM  Results of Phase 3 Trial Evaluating Mercks ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019 Business Wire
Apr-12-19 11:08AM  Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group Zacks
10:38AM  Merck KGaA Signs Versum Buyout Deal; Entegris Receives Termination Payment Benzinga
10:30AM  Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal Zacks
10:07AM  Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals Reuters
09:42AM  5 things to know about Hookipa Pharma ahead of its IPO MarketWatch
08:26AM  Merck KGaA to buy Versum in all-cash deal valued at 5.8 billion euros MarketWatch
07:47AM  The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug Benzinga
Apr-11-19 05:45PM  FDA Approves Expanded Monotherapy Label for Mercks KEYTRUDA® (pembrolizumab) Business Wire
02:57PM  What Medicare for All would do to the health-care sector MarketWatch
12:33PM  NYC Mandates Measles Vaccinations; Merck Is The Exclusive Manufacturer Benzinga
10:03AM  Intercept Reports Additional Positive Data From NASH Study Zacks
09:53AM  Seattle Genetics' Adcetris Progresses Well Amid Competition Zacks
06:33AM  Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock InvestorPlace
Apr-10-19 06:19PM  What the New York City Measles Emergency Means For Vaccine-Maker Merck Motley Fool
03:24PM  Here's what to expect from the stock market next month Investopedia
10:16AM  Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval Zacks
10:14AM  AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer Zacks
08:52AM  Merck & Co., Inc. (NYSE:MRK) Is An Attractive Dividend Stock, Here's Why Simply Wall St.
06:45AM  LYNPARZA® (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer Business Wire
Apr-09-19 02:23PM  10 Dow Jones Stocks Holding the Blue Chip Index Back InvestorPlace
10:42AM  Heres Where You Buy 3M Stock for Capital Gains InvestorPlace
Apr-08-19 05:50PM  Merck (MRK) Stock Sinks As Market Gains: What You Should Know Zacks
05:07PM  Versum Materials Says Revised Merck KGaA Buyout Proposal 'Superior' To Entegris Offer Benzinga
10:43AM  Merck KGaA wins Versum's support for sweetened $6.5 billion offer Reuters
10:30AM  Aeglea (AGLE) Reports New Positive Data for Pegzilarginase Zacks
10:08AM  J&J Stock on an Uptrend This Year So Far: More Room to Run? Zacks
09:41AM  The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca Zacks
08:10AM  Merck wins takeover battle for Versum with $6.4bn offer Financial Times
06:16AM  Merck KGaA raises offer for Versum Materials to $53 per share Reuters
06:07AM  Merck KGaA raises offer for Versum Materials to $53 per share Reuters
Apr-06-19 12:00PM  Better Buy: Johnson & Johnson vs. Merck Motley Fool
Apr-05-19 10:03PM  Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead? Zacks
10:20AM  Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU Zacks
09:33AM  Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck Zacks
09:18AM  Diagnosis of Economy Ahead of World Health Day: 6 Picks Zacks
09:17AM  Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval Zacks
Apr-03-19 08:30AM  BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity GlobeNewswire
08:21AM  12 Dividend Stocks That Hedge Funds Love Kiplinger
Apr-02-19 05:58PM  Software company Gluware expands with automated network upgrades American City Business Journals
05:50PM  Merck (MRK) Stock Moves -0.11%: What You Should Know Zacks
02:58PM  BriaCell Announces Clinical Trial Collaboration Agreement with Incyte GlobeNewswire
10:21AM  Trump delays health care vote until after 2020 election Yahoo Finance Video
10:04AM  Merck's Keytruda Gets Nod for First-Line Lung Cancer in China Zacks
09:44AM  Advaxis Up on Positive Early-Stage Immunotherapy Study Data Zacks
06:45AM  Merck Completes Tender Offer to Acquire Immune Design Business Wire
06:30AM  Merck to Hold First-Quarter 2019 Sales and Earnings Conference Call on April 30 Business Wire
Apr-01-19 06:45PM  BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million GlobeNewswire
04:45PM  Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals Business Wire
03:36PM  AstraZeneca's Selumetinib Gets Breakthrough Therapy Status Zacks
03:19PM  Biotech Winners, Losers In Q1 Benzinga
02:27PM  Advaxis Shares Surge After Positive Clinical Trial Updates Benzinga
12:11PM  Biotech News: Why Advaxis Stock Is Soaring Today InvestorPlace
11:19AM  AstraZeneca's Rare Pediatric Genetic Disorder Drug Granted Breakthrough Therapy Designation Benzinga
10:34AM  Bristol-Myers' (BMY) Acquisition of Celgene Looks Certain Zacks
09:52AM  Merck Shares Gain After Lung Cancer Drug Keytruda Approved for Sale In China TheStreet.com
08:53AM  3 Big Pharma Stocks to Add to Your Portfolio This April Zacks
08:30AM  Data for Mercks KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019 Business Wire
06:55AM  Mercks KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy Business Wire
06:30AM  Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1 Business Wire
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; and Eisai Co., Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Merck & Co., Inc.10% OwnerApr 08Buy16.004,121,68365,946,92812,955,016Apr 09 06:27 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Option Exercise58.22192,57211,211,542330,232Mar 27 05:45 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Sale82.38192,57215,863,119137,660Mar 27 05:45 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM